Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Sarcoma 2Rectal Neoplasms 1Oligodendroglioma 1Meningioma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Gliosarcoma 1Glioma 1Glioblastoma 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 7fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Mycophenolic Acid 5Whole-Body Irradiation 4Filgrastim 4fludarabine 3Cytarabine 3Cyclosporine 3Cord Blood Stem Cell Transplantation 3Busulfan 3Transplantation 2Topotecan 2Tacrolimus 2Gene Expression Profiling 2Flow Cytometry 2Etoposide 2Cytogenetic Analysis 2Bone Marrow Transplantation 2Azacitidine 2tipifarnib 1sargramostim 1pegylated granulocyte colony-stimulating factor 1montanide ISA 51 1decitabine and cedazuridine drug combination 1aldesleukin 1X-Rays 1Vorinostat 1Vitamin E 1Tretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Anemia, Refractory, with Excess of Blasts × Semaxinib × Clear all
NCT00005942 2013-01-23

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

National Cancer Institute (NCI)

Phase 1/2 Completed
37 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡